

ALK – Competitive Landscape



LEERINK SWANN

Drug	Company	Structure	Development Stage	Indication	Data
TSR-011	Tesaro		Preclinical	NSCLC	~200 fold potency in gatekeeper mutation NSCLC patients
Xalkori (crizotinib)	Pfizer	Amynopyridine	Marketed	Locally advanced or metastatic ALK positive NSCLC with a companion diagnostic from ABT	1st endpoint ORR - PROFILE (136 pts) - 50% with 41.9 wk median duration; Study 1001 (119 pts) - 61% with 48.1 wk median duration
AF802	Chugai Pharmaceutical		Phase 1/2		
AP-26113	Ariad	Structure undisclosed	Phase 1	Advanced malignancy resistant to current treatment	
ASP-3026	Astellas		Phase 1	Advanced malignancy (solid tumors and B-cell lymphoma)	
LDK378	Novartis		Phase 1	ALK positive NSCLC pts with prior crizotinib treatment	MTD 750mg, ORR 81% among 26 pts receive 400mg LDK378
GSK2141795	GSK		Phase 1	Solid tumors or lymphomas	
CEP-28122		Diaminopyrimidine	Preclinical, IND expected		
X-276	Xcovery	Structure undisclosed	Preclinical		
F91873 and F91874		Pyridoisoquinoline	Preclinical		
PHA-E429		Pyrrolopyrazole	Preclinical		

Source: Company reports, ClinicalTrial.gov, Leerink Swann